Trial
NCT03241017
Durvalumab in DLBCL After Autologous Transplant
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Insel Gruppe AG, University Hospital Bern
Collaborators
Celgene
Condition
Lymphoma, Large B-Cell, Diffuse
Intervention
Durvalumab
Why stopped
Celgene withdrew the support for this study (Durvalumab cannot be provided)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-04-09